| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 1, Issue 4 391-398, Copyright © 1995 by American Association for Cancer Research
RM Orr, DC Talbot, WG Aherne, TC Fisher, P Serafinowski and KR Harrap
Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, and Cancer Research Campaign Molecular and Cellular Pharmacology Group, School of Biological Sciences, University of Manchest.
2-Chloro-2'-deoxyadenosine, (CldAdo) resistance was developed in the W1L2 human B lymphoblastoid (resistance factor, 160) and L1210 murine leukemia (resistance factor, 605) cell lines by continuous exposure to CldAdo. Cross-resistance studies showed that while the variant lines generally retained sensitivities to 9-beta-D-arabinofuranosyladenine (in the presence of 2'-deoxycoformycin), hydroxyurea, and Adriamycin, both were highly cross-resistant to 1-beta-D-arabinofuranosylcytosine (ara-C), 2', 2'-difluorodeoxycytidine, and 9-beta-D-arabinofuranosyl-2-fluoroadenine. Measurement of both phosphorylating and degrading enzyme activities demonstrated that initial phosphorylation of CldAdo and 2'-deoxycytidine were severely impaired in cell extracts from the resistant lines, whereas adenosine kinase activity remained unaffected and there was no apparent increase in cytoplasmic deoxynucleotidase activity using dCMP as substrate. Since previous reports indicated that either overexpression of Bcl-2 protein following bcl-2 transfection into cells resulted in, or high dCTP pools contributed to, ara-C resistance in experimental cell models, both of these parameters were assessed and found not to contribute to CldAdo resistance in the murine leukemia and human B lymphoblastoid cells. These studies show that a deficiency of 2'-deoxycytidine kinase activity is a major determinant of CldAdo acquired resistance in both the murine and human lymphoid lines.
This article has been cited by other articles:
|
|
 |
|
  C. Smal, D. Vertommen, L. Bertrand, S. Ntamashimikiro, M. H. Rider, E. Van Den Neste, and F. Bontemps Identification of in Vivo Phosphorylation Sites on Human Deoxycytidine Kinase: ROLE OF SER-74 IN THE CONTROL OF ENZYME ACTIVITY J. Biol. Chem., February 24, 2006; 281(8): 4887 - 4893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Jordheim, E. Cros, M.-H. Gouy, C. M. Galmarini, S. Peyrottes, J. Mackey, C. Perigaud, and C. Dumontet Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug Clin. Cancer Res., August 15, 2004; 10(16): 5614 - 5621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cardoen, E. Van Den Neste, C. Smal, J.-F. Rosier, A. Delacauw, A. Ferrant, G. Van den Berghe, and F. Bontemps Resistance to 2-Chloro-2'-deoxyadenosine of the Human B-cell Leukemia Cell Line EHEB Clin. Cancer Res., November 1, 2001; 7(11): 3559 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mansson, T. Spasokoukotskaja, J. Sallstrom, S. Eriksson, and F. Albertioni Molecular and Biochemical Mechanisms of Fludarabine and Cladribine Resistance in a Human Promyelocytic Cell Line Cancer Res., December 1, 1999; 59(23): 5956 - 5963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K Morris, J. M Kolesar, and J. G Kuhn Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 94 - 109. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
